251 related articles for article (PubMed ID: 19571807)
1. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
You JH; Tsui KK; Wong RS; Cheng G
Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
Patrick AR; Avorn J; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.
Eckman MH; Rosand J; Greenberg SM; Gage BF
Ann Intern Med; 2009 Jan; 150(2):73-83. PubMed ID: 19153410
[TBL] [Abstract][Full Text] [Related]
4. Genetic testing for warfarin dosing? Not yet ready for prime time.
Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
[No Abstract] [Full Text] [Related]
5. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
[TBL] [Abstract][Full Text] [Related]
6. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
[TBL] [Abstract][Full Text] [Related]
7. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.
Verhoef TI; Redekop WK; Langenskiold S; Kamali F; Wadelius M; Burnside G; Maitland-van der Zee AH; Hughes DA; Pirmohamed M
Pharmacogenomics J; 2016 Oct; 16(5):478-84. PubMed ID: 27272045
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics and warfarin therapy.
Ndegwa S
Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
[TBL] [Abstract][Full Text] [Related]
10. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
11. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
12. [Possible application of pharmacogenomics to warfarin therapy].
Murata M
Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
[TBL] [Abstract][Full Text] [Related]
13. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R
Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631
[TBL] [Abstract][Full Text] [Related]
14. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.
Kim MJ; Huang SM; Meyer UA; Rahman A; Lesko LJ
J Clin Pharmacol; 2009 Feb; 49(2):138-46. PubMed ID: 19179293
[TBL] [Abstract][Full Text] [Related]
15. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
16. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of genotype-guided dosing of warfarin.
Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
[TBL] [Abstract][Full Text] [Related]
18. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.
Fung E; Patsopoulos NA; Belknap SM; O'Rourke DJ; Robb JF; Anderson JL; Shworak NW; Moore JH
Semin Thromb Hemost; 2012 Nov; 38(8):893-904. PubMed ID: 23041981
[TBL] [Abstract][Full Text] [Related]
19. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
20. Role of warfarin pharmacogenetic testing in clinical practice.
Tan GM; Wu E; Lam YY; Yan BP
Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
